版本:
中国

BRIEF-Tetraphase Pharmaceuticals' TP-6076 selected by Carb-X to receive $4 mln in research funding

March 30 Tetraphase Pharmaceuticals Inc

* Tetraphase Pharmaceuticals' TP-6076 selected by Carb-X to receive $4 million in research funding

* Tetraphase Pharmaceuticals Inc says in preclinical research, TP-6076 has demonstrated potent activity against MDR bacteria Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐